FINWIRES · TerminalLIVE
FINWIRES

Microchip Technology Insider Sold Shares Worth $36,881,124, According to a Recent SEC Filing

By

-- Steve Sanghi, Director, President, CEO, and Chair of the Board, on April 23, 2026, sold 416,581 shares in Microchip Technology (MCHP) for $36,881,124. Following the Form 4 filing with the SEC, Sanghi has control over a total of 9,495,805 common shares of the company, with 9,495,805 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/827054/000118192826000018/xslF345X05/wk-form4_1777322521.xml

Related Articles

Asia

Santana Minerals Advances South Island Gold Project on Approvals Progress, Exploration Upside

Santana Minerals (ASX:SMI, NZE:SMI) reported steady progress across permitting, financing, and exploration at its Bendigo-Ophir Gold Project in New Zealand's South Island, highlighted by advancing fast-track approvals (FTA), a AU$130 million capital raise, and continued high-grade drilling success at the Rise and Shine deposit, according to a Tuesday filing with the Australian and New Zealand bourses.The company said the FTA process for Bendigo-Ophir remains a priority, with a consent decision set for Oct. 29 and engagement with the FTA expert panel already underway.Key infrastructure milestones include a finalized road access agreement with the Central Otago District Council and the creation of a NZ$1.3 million annual community fund.Operational readiness is advancing through key mining fleet agreements with Komatsu, alongside exploration success at the Rise and Shine deposit, where mineralization has been extended to over 2.2 kilometers with strong high-grade intercepts.The company completed a AU$130 million capital raising alongside a AU$4.1 million share purchase plan, strengthening funding for its predominantly debt-funded development plan, and closed the third quarter with a net cash balance of AU$184 million after payables.

$ASX:SMI$NZE:SMI
Asia

Xizhi Technology Raises HK$2.4 Billion From Hong Kong IPO Ahead of Debut

Shanghai Xizhi Technology (HKG:1879) raised HK$2.38 billion in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$183.20 per H-share, the top of the offer price range, according to a Monday after-market filing with the Hong Kong Stock Exchange.The China-based optoelectronic computing company offered 13.8 million H-shares in the global offering.The Hong Kong public offer was 5,784.70 times subscribed, with a final allocation of 2.8 million shares, representing 20% of the total offering.The international offering was 53.83 times subscribed, with a final allocation of 11 million shares, or 80% of the total offering.An over-allocation of 2.1 million shares was made under the global offering.Cornerstone investors, including Alibaba Investment, GIC, Baillie Gifford, BlackRock, Fidelity International, Schroders, Temasek, and CM Shanghai Fund, were allotted a combined 9 million shares, according to the filing.Xizhi Tech is scheduled to debut on the Hong Kong bourse on Tuesday, April 28.

$HKG:1879
Research

Research Alert: Alexandria Real Estate Equities Q1: Dispositions Accelerate, Renewal Rates Down

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ARE reported Q1 revenue of $671M (-11.5% Y/Y and $25M below consensus) vs. $754M a year ago. Rental income declined 12.1% to $653M, reflecting lower occupancy and significant pricing pressure on lease renewals across the portfolio. Rental rate changes on renewals and re-leasing showed a steep 15.0% decline (-15.8% cash basis), a dramatic reversal from the -5.5% cash renewal rate in Q4 2025. Management updated cash rental rate guidance to -14% to -7%, declining a further 300 bps since February as market conditions deteriorated. We expect continued pressure on re-leasing growth in full-year 2026 as ARE continues to optimize its portfolio of properties amid challenging life science market dynamics. The significant deterioration in renewal spreads from Q4 2025 to Q1 2026 highlights the difficult operating environment facing life science real estate, with both occupancy headwinds and rental rate pressures creating a challenging backdrop for near-term financial performance and cash flow generation.

$ARE